镓68 PSMA PET/CT能否成为根治性前列腺切除术后生化复发前列腺癌患者决策策略的新工具?一项初步单中心系列研究
回顾性分析40例根治性前列腺切除术后生化复发的前列腺癌患者,其中13例在RP后、14例在挽救性RT后、13例在挽救性或辅助ADT后行镓68 PSMA-11 PET/CT,PSA范围0.1–1.62 ng/ml(中位0.51 ng/ml)。31/40例(77.5%)PET/CT阳性,28例(70%)治疗决策因此改变。作者认为该检查可能有助于再分期并改变决策,但需前瞻性更大样本研究。
要点
- PSMA PET/CT在RP后生化复发患者中阳性率77.5%(31/40),常见部位为盆腔外淋巴结(12例)和骨(8例)。
- PET/CT结果使70%(28/40)患者的治疗决策发生改变。
- 9例(22.5%)存在两个不同复发部位,阅片需全面评估。
核心结论
- 镓68 PSMA-11(HBED-CC)PET/CT可能成为RP、RT或ADT后生化复发前列腺癌患者再分期的有用工具,并可能改变高达70%患者的决策过程。
- 作者指出需要前瞻性、更大样本系列研究来确定该工具在前列腺癌分期和治疗策略中的正确作用。
研究设计与样本
- 回顾性分析40例根治性前列腺切除术后生化复发的前列腺癌患者。
- 13/40例在RP后因生化复发、14/40例在挽救性RT后、13/40例在挽救性或辅助ADT后行镓68 PSMA-11(HBED-CC)PET/CT。
- PSA水平范围0.1–1.62 ng/ml,中位值0.51 ng/ml。
- 评估镓68 PSMA-11(HBED-CC)PET/CT额外数据对多学科肿瘤委员会决策过程的影响。
关键影像表现/征象
- 31/40例(77.5%)镓68 PSMA-11(HBED-CC)PET/CT显示阳性发现。
- 阳性部位:5例前列腺床、9例盆腔淋巴结、12例盆腔外淋巴结、8例骨 level。
- 9例(22.5%)呈现两个不同复发部位。
临床应用与阅片要点
- 镓68 PSMA-11(HBED-CC)PET/CT数据使28例(70%)患者的治疗策略发生改变。
- 作者认为该检查可能用于RP、RT或ADT后生化复发患者的再分期,并可能改变决策过程。
- 作者指出需前瞻性、更大样本系列研究来确定其正确作用。
局限性
- 原文标题注明为初步、单中心系列研究。
- 作者指出需要前瞻性、更大样本系列研究来确定该工具的正确作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To evaluate the impact of gallium68 PSMA-11 (HBED-CC)-PET/CT on decision-making strategy of patients with relapsing prostate cancer (PC) presenting a second biochemical relapse after radical prostatectomy (RP) and salvage RT or salvage androgen deprivation therapy (ADT).
MATERIALS AND METHODS: 40 patients were retrospectively analyzed. All of them had received prostatectomy. Thirteen out of 40 were addressed to gallium68 PSMA-11 (HBED-CC)-PET/CT for a biochemical relapse after RP, 14/40 after a salvage RT and 13/40 after salvage or adjuvant ADT. The PSA level ranged between 0.1 and 1.62 ng/ml (median value: 0.51 ng/ml). We studied the impact on the decision-making process of a multidisciplinary tumor board of additional data obtained from gallium68 PSMA-11 (HBED-CC)-PET/CT.
RESULTS: Thirty-one out of 40 evaluated patients showed positive findings at gallium68 PSMA-11 (HBED-CC)-PET/CT (77.5%). Of them, five were positive in the prostatic bed, nine in the pelvic nodes, twelve in nodes outside the pelvis and eight at bone level. Nine patients presented two different sites of relapse (22.5%). Gallium68 PSMA-11 (HBED-CC)-PET/CT data changed the therapeutic approach in 28 patients (70%).
CONCLUSIONS: Gallium68 PSMA-11 (HBED-CC)-PET/CT can be a useful tool in the restaging of post-RP, RT or ADT patients presenting biochemical relapse of PC and it could change the decision-making process in up of 70% of these patients. Prospective, larger series are needed to establish the correct role of this very promising tool in the staging and therapeutic approach of PC patients.
引用
- De Bari B, Mazzola R, Aiello D, et al. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiol Med. 2018. PMID: 29687208. doi:10.1007/s11547-018-0890-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。